Table 3.
Participants withdrawn prematurely from treatment, N (%)
| All Participants | Treatment- Naïve | PI-Naïve but Treatment- Experienced | Toxicity Switch from Other PI Regimen | Toxicity Switch from Prior Non-PI Regimen | HCV Coinfection | Prior PI | Prior Non-PI Regimen | |
|---|---|---|---|---|---|---|---|---|
| Participants Initiating Study | (N = 2122) | (N = 413) | (N = 265) | (N = 161) | (N = 201) | (N = 287) | (N = 1386) | (N = 1640) |
| Reason for withdrawal | ||||||||
| Adverse event | 44 (2.1) | 9 (2.2) | 7 (2.6) | 3 (1.9) | 5 (2.5) | 5 (1.7) | 27 (1.9) | 34 (2.1) |
| Lost to follow-up | 42 (2.0) | 17 (4.1) | 1 (0.4) | 2 (1.2) | 1 (0.5) | 12 (4.2) | 23 (1.7) | 23 (1.4) |
| Lack of adherence | 26 (1.2) | 5 (1.2) | 4 (1.5) | 1 (0.6) | 4 (2.0) | 7 (2.4) | 17 (1.2) | 20 (1.2) |
| Virologic failure | 18 (0.8) | 1 (0.2) | — | 1 (0.6) | — | — | 17 (1.2) | 16 (1.0) |
| Intercurrent illness | 11 (0.5) | 4 (1.0) | 2 (0.8) | — | 2 (1.0) | — | 5 (0.4) | 7 (0.4) |
| Death | 7 (0.3) | 4 (1.0) | — | — | — | 3 (1.0) | 3 (0.2) | 3 (0.2) |
| Other | 43 (2.0) | 9 (2.2) | 5 (1.9) | 1 (0.6) | 6 (3.0) | 3 (1.0) | 28 (2.0) | 33 (2.0) |
| None provided | 23 (1.1) | 4 (1.0) | 5 (1.9) | 2 (1.2) | — | 3 (1.0) | 14 (1.0) | 19 (1.2) |
| All | 214 (10.1) | 53 (12.8) | 24 (9.11) | 10 (6.2) | 18 (9.0) | 33 (11.5) | 134 (9.7) | 155 (9.5) |
HCV = hepatitis C virus; PI = protease inhibitor.